Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and total-body irradiation
(TBI) before a donor stem cell transplant helps stop the growth of cancer cells. It also
stops the patient's immune system from rejecting the donor's stem cells. The donated stem
cells may replace the patient's immune system and help destroy any remaining cancer cells
(graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte
infusion) that have been treated in the laboratory after the transplant may help increase
this effect. Sometimes the transplanted cells from a donor can also make an immune response
against the body's normal cells. Giving cyclosporine and alemtuzumab, and removing the T
lymphocyte cells(T cells) from the donor cells before transplant, may stop this from
happening.
PURPOSE: This clinical trial is studying how well giving fludarabine, alemtuzumab, and
total-body irradiation together with donor stem cell transplant and donor white blood cell
(WBC) infusion works in treating patients with chronic phase chronic myelogenous leukemia
(CML) that did not respond to previous imatinib mesylate.